Reuters logo
Celgene's Revlimid improves survival in blood cancer patients
July 11, 2013 / 11:47 AM / 4 years ago

Celgene's Revlimid improves survival in blood cancer patients

July 11 (Reuters) - Celgene Corp said a late-stage trial of its cancer drug Revlimid met the main goal of improving survival in blood cancer patients.

The drug was tested in patients with newly diagnosed multiple myeloma, and showed a statistically significant improvement in survival, without the cancer worsening.

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below